BiotechTube

ARX201 + ARX201 + ARX201

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Growth Hormone Deficiency

Conditions

Growth Hormone Deficiency

Trial Timeline

Jul 1, 2008 → Oct 1, 2009

NCT ID
NCT00778518

About ARX201 + ARX201 + ARX201

ARX201 + ARX201 + ARX201 is a phase 2 stage product being developed by Merck for Growth Hormone Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT00778518. Target conditions include Growth Hormone Deficiency.

What happened to similar drugs?

11 of 20 similar drugs in Growth Hormone Deficiency were approved

Approved (11) Terminated (1) Active (9)
✅PEG-somatropinSun PharmaceuticalApproved
✅PEG-somatropin + PEG-somatropinSun PharmaceuticalApproved
✅Saizen® solution for injection (referred as Saizen®)MerckApproved
✅Saizen + SaizenMerckApproved
✅EverolimusNovartisApproved
✅somatropin + somatropin + somatropinNovo NordiskApproved
✅somatropin + placeboNovo NordiskApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00778518Phase 2Completed

Competing Products

20 competing products in Growth Hormone Deficiency

See all competitors
ProductCompanyStageHype Score
SomatropinEli LillyPhase 3
40
Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)Eli LillyPre-clinical
26
HER3-DXdDaiichi SankyoPre-clinical
26
ErlotinibAstellas PharmaPhase 2
27
radio-labeled naquotinib + naquotinibAstellas PharmaPhase 1
21
pegylated Somatropin + pegylated Somatropin + Jintropin AQSun PharmaceuticalPhase 2
35
PEG-somatropinSun PharmaceuticalApproved
39
PEG-somatropin + PEG-somatropinSun PharmaceuticalApproved
39
PEG-somatropinSun PharmaceuticalPhase 3
40
Somatropin + SomatropinEli LillyPhase 3
40
Somatropin + SomatropinEli LillyPhase 3
40
somatropin, rDNA origin, for injectionEli LillyPhase 3
40
Sterile becaplermin gel vs. sterile placebo gel treatment 1Johnson & JohnsonPre-clinical
26
ABT-414AbbViePre-clinical
26
Saizen® A + Saizen® BMerckPhase 3
40
Saizen® solution for injection (referred as Saizen®)MerckApproved
43
Cetuximab + FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)MerckPhase 3
40
Saizen + SaizenMerckApproved
43
MiransertibMerckPhase 2
39
MiransertibMerckPhase 1/2
24